Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Oktawia Nilsson"'
Autor:
Claire L Lyons, Elaine Cowan, Oktawia Nilsson, Manca Mohar, Pablo Peña-Martínez, Lena Eliasson, Jens O Lagerstedt
Publikováno v:
PLoS ONE, Vol 19, Iss 11, p e0311039 (2024)
Apolipoprotein A-I (ApoA-I), the primary component of high-density lipoprotein (HDL) cholesterol primes β-cells to increase insulin secretion, however, the mechanisms involved are not fully defined. Here, we aimed to confirm ApoA-I receptors in β-c
Externí odkaz:
https://doaj.org/article/afa99b8bdf8b4321a1e44d44ed27a9f7
Autor:
Oktawia Nilsson, Mikaela Lindvall, Laura Obici, Simon Ekström, Jens O. Lagerstedt, Rita Del Giudice
Publikováno v:
Journal of Lipid Research, Vol 62, Iss , Pp 100004- (2021)
Apolipoprotein A-I (ApoA-I) of high density lipoproteins (HDLs) is essential for the transportation of cholesterol between peripheral tissues and the liver. However, specific mutations in ApoA-I of HDLs are responsible for a late-onset systemic amylo
Externí odkaz:
https://doaj.org/article/5156d5a2fef84b59928153eae4802ab7
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 1; Pages: 318
Apolipoprotein A-I (ApoA-I) amyloidosis is a rare protein misfolding disease where fibrils of the N-terminal domain of the protein accumulate in several organs, leading to their failure. Although ApoA-I amyloidosis is systemic, the different amyloido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cacad015f1b1e8018b27fc042b0d13fc
https://hdl.handle.net/11588/908545
https://hdl.handle.net/11588/908545
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864:2822-2834
Prolonged hyperglycemia in poorly controlled diabetes leads to an increase in reactive glucose metabolites that covalently modify proteins by non-enzymatic glycation reactions. Apolipoprotein A-I (apoA-I) of high-density lipoprotein (HDL) is one of t
Autor:
Ilaria Iacobucci, Oktawia Nilsson, Maria Chiara Monti, Daria Maria Monti, Rita Del Giudice, Jens O. Lagerstedt, Joan Domingo-Espín
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1863:3038-3048
Twenty Apolipoprotein A-I (ApoA-I) variants are responsible for a systemic hereditary amyloidosis in which protein fibrils can accumulate in different organs, leading to their failure. Several ApoA-I amyloidogenic mutations are also associated with h
Autor:
Jens O. Lagerstedt, Rita Del Giudice, Oktawia Nilsson, Laura Obici, Simon Ekström, Mikaela Lindvall
Publikováno v:
Biophysical Journal. 118:215a-216a
Autor:
Caitriona Grönberg, Rita Del Giudice, Oktawia Nilsson, Lena Eliasson, Mototsugu Nagao, Jens O. Lagerstedt
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1866:165613
The increase of plasma levels of high-density lipoproteins and Apolipoprotein A-I (ApoA-I), its main protein component, has been shown to have a positive action on glucose disposal in type 2 diabetic patients. The current study investigates the unexp
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Apolipoprotein A-I (apoA-I) in high-density lipoprotein (HDL) provides cardiovascular protection. Synchrotron radiation circular dichroism (SRCD) spectroscopy was used to analyze the dynamic solution structure of the apoA-I protein in the apo- and HD
Autor:
Maria Lindahl, Joan Domingo-Espín, Jens O. Lagerstedt, Karin G. Stenkula, Samuel W. Cushman, Oktawia Nilsson-Wolanin
Publikováno v:
Diabetes. 65(7)
Apolipoprotein A-I (apoA-I) of HDL is central to the transport of cholesterol in circulation. ApoA-I also provides glucose control with described in vitro effects of apoA-I on β-cell insulin secretion and muscle glucose uptake. In addition, apoA-I i